Acasunlimab  (Synonyms: GEN1046)

Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer^[1][2].

Ig(G1-kappa_G1-lambda2)

Human IgG1 kappa, Isotype Control

Human

TNFRSF9 & CD274

Acasunlimab (GEN1046; 0.001-1 μM; 0-525 min) promotes interactions between dendritic cells and T cells and enhances T-cell activation^[1].
Acasunlimab (0.001-1 μM; 48 h; PD-L1⁺ Tumor Cells) induces dose-dependent, conditional T-cell proliferation and cytokine production and enhances antigen-specific T-cell–mediated cytotoxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Acasunlimab (GEN1046; 5 mg/kg; twice weekly for three cycles) has antitumor activity and inhibits tumor growth in double knock-in (dKI) transgenic C57BL/6 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3604  [NCBI] & 29126  [NCBI]

Q07011 & Q9NZQ7

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.86 kDa

2253937-12-9

Liquid

Colorless to light yellow

[Acasunlimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Ig(G1-kappa_G1-lambda2)

• 
  Immobilized Human 4-1BB/CD137 Protein (ECD, His Tag) can bind Acasunlimab. The EC₅₀ for this effect is 5.74 ng/mL.
• 
  Immobilized Human PD-L1/B7-H1 Protein (ECD) can bind Acasunlimab. The EC₅₀ for this effect is 11.27 ng/mL.

• [1]. Muik A, et, al. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022 May 2;12(5):1248-1265.  [Content Brief]

  [2]. Gao Y, et, al. Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. FEBS Open Bio. 2022 Dec;12(12):2166-2178.  [Content Brief]